Bridgebio Pharma Inc (BBIO) Stock Price, Quote & News

Company Profile

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 391 9740

Website: bridgebio.com

Address:

3160 Porter Drive, Suite 250, Palo Alto, United States

supplySHOCK Jun. 4 at 11:04 AM

$SOLV $BMRN $BBIO $TW display

0 · Reply

supplySHOCK Jun. 4 at 8:15 AM

$BBIO $TW $ARWR $BURL direct

0 · Reply

supplySHOCK Jun. 3 at 11:27 PM

$SOLV $BMRN $BBIO $TW rules

0 · Reply

Nosh Jun. 3 at 6:47 PM

$BBIO Starter in the morning.

0 · Reply

LMXPERTEN Jun. 3 at 6:17 PM

$BBIO loaded up! 🙏 Thank you sellers

0 · Reply

sampeper Jun. 3 at 12:06 PM

$BBIO Canaccord Genuity Initiates BridgeBio Pharma at Buy With $104 Price Target https://www.marketscreener.com/news/canaccord-genuity-initiates-bridgebio-pharma-at-buy-with-104-price-target-ce7f5ddfdd8fff23

0 · Reply

DonCorleone77 Jun. 3 at 11:03 AM

$BBIO Canaccord starts BridgeBio on Attruby launch, pipeline Canaccord initiated coverage of BridgeBio with a Buy rating and $104 price target. The firm is "bullish as ever" on the transthyretin amyloid cardiomyopathy space. Canaccord cites BridgeBio's continued launch progress with Attruby and its three other rare disease launches coming in the next 12-18 months for the Buy rating. The firm is also bullish on infigratinib in achondroplasia, citing the drug's "strong efficacy, clean safety," and oral route of administration versus the once daily or weekly injections from competitors.

0 · Reply

SuperGreenToday Jun. 3 at 12:29 AM

$BBIO Share Price: $63.87 Contract Selected: Nov 20, 2026 $65 Calls Buy Zone: $6.97 – $8.61 Target Zone: $12.38 – $15.13 Potential Upside: 68% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

sampeper Jun. 2 at 12:27 PM

$BBIO Mizuho Markets Americas LLC Grows Holdings in BridgeBio Pharma, Inc. $BBIO https://www.marketbeat.com/instant-alerts/filing-mizuho-markets-americas-llc-grows-holdings-in-bridgebio-pharma-inc-bbio-2026-05-23/#google_vignette

0 · Reply

sampeper Jun. 2 at 12:20 PM

$BBIO breaking news: Geode Capital Management LLC Purchases 502,582 Shares of BridgeBio Pharma, Inc. $BBIO Geode Capital Management increased its BridgeBio Pharma stake by 12.9% in the fourth quarter, buying 502,582 shares and lifting its holdings to 4.41 million shares worth about $344.7 million. https://www.marketbeat.com/instant-alerts/filing-geode-capital-management-llc-purchases-502582-shares-of-bridgebio-pharma-inc-bbio-2026-06-02/

0 · Reply

BridgeBio Pharma Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T11:44:52.000Z - 1 day ago

Canaccord starts BridgeBio on Attruby launch, pipeline

Jun 3, 2026, 7:00 AM EDT - 1 day ago

BridgeBio Pharma Slides: Corporate presentation

2026-06-03T10:13:20.000Z - 1 day ago

BridgeBio initiated with a Buy at Canaccord

2026-05-28T15:58:17.000Z - 7 days ago

BridgeBio price target raised to $98 from $94 at Morgan Stanley

2026-05-27T12:17:42.000Z - 8 days ago

BridgeBio announces FDA acceptance, priority review of BBP-418 NDA

May 27, 2026, 7:30 AM EDT - 8 days ago

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

2026-05-26T09:01:09.000Z - 9 days ago

BridgeBio downgraded to Market Perform from Outperform at Raymond James

2026-05-18T20:22:46.000Z - 17 days ago

BridgeBio initiated with a Neutral at Citi

May 12, 2026, 5:20 PM EDT - 23 days ago

BridgeBio Pharma Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T13:20:39.000Z - 23 days ago

BridgeBio shares have ‘clear path’ to $90s, says JPMorgan

May 12, 2026, 7:30 AM EDT - 23 days ago

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

2026-05-11T19:59:22.000Z - 24 days ago

BridgeBio announces new data of Phase 3 ATTRibute-CM study at Heart Failure 2026

May 11, 2026, 9:30 AM EDT - 24 days ago

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

2026-05-11T10:45:29.000Z - 24 days ago

BridgeBio price target raised to $110 from $100 at H.C. Wainwright

May 8, 2026, 4:01 PM EDT - 27 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-05-08T18:38:04.000Z - 27 days ago

BridgeBio price target raised to $130 from $125 at Evercore ISI

2026-05-08T14:57:27.000Z - 27 days ago

BridgeBio price target lowered to $94 from $98 at Morgan Stanley

2026-05-08T11:59:17.000Z - 27 days ago

BridgeBio price target raised to $114 from $100 at Bernstein

2026-05-08T10:21:40.000Z - 27 days ago

BridgeBio files automatic mixed securities shelf

May 7, 2026, 4:30 PM EDT - 4 weeks ago

BridgeBio Pharma Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

BridgeBio Pharma Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

BridgeBio Pharma Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 4 weeks ago

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

May 7, 2026, 4:00 PM EDT - 4 weeks ago

BridgeBio Pharma Slides: Corporate presentation

2026-05-07T03:52:09.000Z - 4 weeks ago

BridgeBio receives regulatory approval in Brazil for Beyonttra

May 6, 2026, 4:01 PM EDT - 4 weeks ago

BridgeBio to Participate in May and June Investor Conferences

May 6, 2026, 7:30 AM EDT - 4 weeks ago

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

May 5, 2026, 7:30 AM EDT - 4 weeks ago

BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE

May 4, 2026, 7:30 AM EDT - 4 weeks ago

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

Apr 30, 2026, 7:30 AM EDT - 5 weeks ago

BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

2026-04-29T13:59:42.000Z - 5 weeks ago

BridgeBio price target raised to $102 from $95 at Truist

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

BridgeBio Pharma Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

BridgeBio Pharma Proxy statement: Proxy filing

Mar 30, 2026, 3:30 PM EDT - 2 months ago

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Mar 30, 2026, 7:30 AM EDT - 2 months ago

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

Mar 23, 2026, 7:30 AM EDT - 2 months ago

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

Mar 12, 2026, 7:00 AM EDT - 3 months ago

BridgeBio Pharma Slides: Corporate presentation

Mar 11, 2026, 2:00 PM EDT - 3 months ago

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Mar 11, 2026, 12:30 PM EDT - 3 months ago

BridgeBio Pharma Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:00 PM EDT - 3 months ago

BridgeBio Pharma Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 7:30 AM EST - 3 months ago

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

Mar 2, 2026, 3:50 PM EST - 3 months ago

BridgeBio Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:30 PM EST - 3 months ago

BridgeBio Pharma Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

BridgeBio Pharma Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 3 months ago

BridgeBio Pharma Earnings release: Q4 2025

Feb 24, 2026, 4:01 PM EST - 3 months ago

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

Feb 23, 2026, 7:30 AM EST - 3 months ago

BridgeBio to Participate in March Investor Conferences

Feb 17, 2026, 7:30 AM EST - 3 months ago

BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

Feb 12, 2026, 8:00 AM EST - 4 months ago

BridgeBio Pharma Transcript: Study result

Feb 12, 2026, 8:00 AM EST - 4 months ago

BridgeBio Pharma Press release: Study result

Feb 12, 2026, 8:00 AM EST - 4 months ago

BridgeBio Pharma Slides: Study result

Feb 12, 2026, 7:30 AM EST - 4 months ago

BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

Jan 27, 2026, 5:10 PM EST - 4 months ago

CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 1:00 AM EST - 4 months ago

BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

Jan 14, 2026, 4:01 PM EST - 5 months ago

BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027

Jan 12, 2026, 10:30 AM EST - 5 months ago

BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 5 months ago

BridgeBio Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 5 months ago

BridgeBio Pharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 months ago

BridgeBio Pharma Slides: Corporate presentation

Jan 9, 2026, 8:00 AM EST - 5 months ago

BridgeBio Pharma Transcript: Investor Update

Jan 9, 2026, 8:00 AM EST - 5 months ago

BridgeBio Pharma Slides: Investor Update

Jan 5, 2026, 7:30 AM EST - 5 months ago

BridgeBio to Participate in the J.P. Morgan Healthcare Conference

Jan 2, 2026, 7:30 AM EST - 5 months ago

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

Dec 3, 2025, 3:00 PM EST - 6 months ago

BridgeBio Pharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:30 AM EST - 6 months ago

BridgeBio Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 6 months ago

BridgeBio to Participate in December Investor Conferences

Nov 18, 2025, 11:00 AM EST - 7 months ago

BridgeBio Pharma Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 1:15 PM EST - 7 months ago

BridgeBio Pharma Transcript: UBS Global Healthcare Conference 2025

Nov 8, 2025, 10:41 AM EST - 7 months ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Nov 7, 2025, 1:00 PM EST - 7 months ago

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Nov 4, 2025, 7:30 AM EST - 7 months ago

BridgeBio to Participate in November Investor Conferences

Nov 3, 2025, 9:58 AM EST - 7 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Nov 3, 2025, 7:30 AM EST - 7 months ago

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

BridgeBio Pharma Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

BridgeBio Pharma Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 7 months ago

BridgeBio Pharma Earnings release: Q3 2025

Oct 29, 2025, 4:01 PM EDT - 7 months ago

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

Oct 29, 2025, 4:00 PM EDT - 7 months ago

BridgeBio Pharma Slides: Corporate Presentation

Oct 29, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Transcript: Study Result

Oct 29, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Press release: Study Result

Oct 29, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Slides: Study Result

Oct 29, 2025, 7:00 AM EDT - 7 months ago

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

Oct 28, 2025, 4:01 PM EDT - 7 months ago

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

Oct 27, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Transcript: Study Result

Oct 27, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Press release: Study Result

Oct 27, 2025, 8:00 AM EDT - 7 months ago

BridgeBio Pharma Slides: Study Result

Oct 27, 2025, 7:00 AM EDT - 7 months ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

Oct 24, 2025, 4:01 PM EDT - 7 months ago

BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Sep 28, 2025, 11:15 AM EDT - 8 months ago

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

Sep 22, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

Sep 10, 2025, 8:00 AM EDT - 9 months ago

BridgeBio Pharma Transcript: Investor Update

Sep 10, 2025, 8:00 AM EDT - 9 months ago

BridgeBio Pharma Slides: Investor Update

Sep 8, 2025, 3:20 PM EDT - 9 months ago

BridgeBio Pharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 6, 2025, 2:30 PM EDT - 9 months ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

Sep 4, 2025, 2:10 PM EDT - 9 months ago

BridgeBio Pharma Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:30 AM EDT - 9 months ago

BridgeBio Pharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Sep 2, 2025, 7:30 AM EDT - 9 months ago

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Aug 30, 2025, 7:15 AM EDT - 9 months ago

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

Aug 27, 2025, 7:30 AM EDT - 10 months ago

BridgeBio to Participate in September Investor Conferences

Aug 25, 2025, 7:30 AM EDT - 10 months ago

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Aug 19, 2025, 5:30 PM EDT - 10 months ago

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

Aug 5, 2025, 4:30 PM EDT - 10 months ago

BridgeBio Pharma Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 10 months ago

BridgeBio Pharma Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 10 months ago

BridgeBio Pharma Earnings release: Q2 2025

Aug 5, 2025, 4:01 PM EDT - 10 months ago

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Aug 5, 2025, 7:00 AM EDT - 10 months ago

BridgeBio Pharma Slides: Corporate Presentation

Jul 30, 2025, 12:37 PM EDT - 11 months ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN INSM

Jul 23, 2025, 7:30 AM EDT - 11 months ago

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1

Jul 22, 2025, 7:30 AM EDT - 11 months ago

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET

Jul 11, 2025, 8:00 AM EDT - 11 months ago

BridgeBio Pharma Transcript: Study Update

Jul 11, 2025, 8:00 AM EDT - 11 months ago

BridgeBio Pharma Slides: Study Update

Jul 7, 2025, 6:29 PM EDT - 11 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BMRN GILD INSM XBI

supplySHOCK Jun. 4 at 11:04 AM

$SOLV $BMRN $BBIO $TW display

0 · Reply

supplySHOCK Jun. 4 at 8:15 AM

$BBIO $TW $ARWR $BURL direct

0 · Reply

supplySHOCK Jun. 3 at 11:27 PM

$SOLV $BMRN $BBIO $TW rules

0 · Reply

Nosh Jun. 3 at 6:47 PM

$BBIO Starter in the morning.

0 · Reply

LMXPERTEN Jun. 3 at 6:17 PM

$BBIO loaded up! 🙏 Thank you sellers

0 · Reply

sampeper Jun. 3 at 12:06 PM

0 · Reply

DonCorleone77 Jun. 3 at 11:03 AM

0 · Reply

SuperGreenToday Jun. 3 at 12:29 AM

0 · Reply

sampeper Jun. 2 at 12:27 PM

0 · Reply

sampeper Jun. 2 at 12:20 PM

0 · Reply

sampeper Jun. 2 at 12:18 PM

$BBIO Understanding ATTR-CM: A Powerful Conversation https://blackdoctor.com/understanding-attr-cm-a-powerful-conversation/

0 · Reply

ELI666 Jun. 1 at 4:24 PM

$BBIO Good news very soon!! ✔️ STRONG BUY!

1 · Reply

sampeper May. 30 at 12:48 AM

$BBIO Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) https://www.stocktitan.net/sec-filings/BBIO/schedule-13g-bridge-bio-pharma-inc-passive-investment-disclosure-5-44f5a8fab0dd.html

0 · Reply

Nomorelies May. 30 at 12:24 AM

$BBIO Can someone explain why this is down so much?

2 · Reply

sampeper May. 29 at 4:15 PM

$BBIO ceo neil Kumar said:

0 · Reply

sampeper May. 29 at 4:11 PM

$BBIO BridgeBio Wins FDA Priority Review for BBP-418 Therapy https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2187398/bridgebio-wins-fda-priority-review-for-bbp-418-therapy/

0 · Reply

prismmarketview May. 28 at 2:45 PM

$BBIO 🚨 FDA accepts the BBP‑418 NDA for LGMD2I/R9 and grants Priority Review. PDUFA date: Nov 27, 2026. Potential first ever approved drug for any limb‑girdle muscular dystrophy. #BBIO #Biotech #RareDisease https://prismmarketview.com/bridgebios-bbp-418-nears-first-ever-limb-girdle-md-treatment/

0 · Reply

sampeper May. 28 at 11:39 AM

$BBIO Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data https://www.tipranks.com/news/ratings/analyst-lifts-bridgebio-price-target-to-98-as-bbp418-becomes-core-growth-driver-following-strong-phase-3-data-ratings-news

0 · Reply

sampeper May. 28 at 11:36 AM

$BBIO BBIO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $110 https://www.gurufocus.com/news/8888258/bbio-reiterates-by-hc-wainwright-co-price-target-maintained-at-110

0 · Reply

sampeper May. 28 at 11:35 AM

$BBIO Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $98 https://www.moomoo.com/news/post/70661607/morgan-stanley-maintains-bridgebio-pharma-bbious-with-buy-rating-raises?level=1&data_ticket=1776416983151450

0 · Reply

MikeyNJ May. 27 at 3:15 PM

$BBIO the company is firing on all cylinders. Great time for long term investors to start and add on to positions. The PFE tafamidis patent litigation stopped all the upward momentum and continues to act as a headwind. In my opinion, it has created a buying opportunity. Buy it and put it away. This is a winner.

1 · Reply

notreload_ai May. 27 at 1:05 PM

$BBIO BBP-418 receives FDA Priority Review with a November 27, 2026 PDUFA date. If approved, it would be the first therapy for LGMD2I/R9 and any form of limb-girdle muscular dystrophy. https://notreload.xyz/xy/fda-fast-tracks-first-treatment-for-lgmd2i-r9/

0 · Reply

Market Cap	12.82B
Revenue (ttm)	502.08M
Net Income (ttm)	-724.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-144.39%
Debt to Equity Ratio	-0.85

Volume	1,968,800
Avg Vol	2,635,374
Day's Range	N/A - N/A
Shares Out	195.86M
Stochastic %K	52%
Beta	0.97
Analysts	Strong Sell
Price Target	$105.37